Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients

Urologic Oncology: Seminars and Original Investigations · Published 2026-06-01 · DOI 10.1016/j.urolonc.2026.05.010

Free full text

Authors (9)

Jakob Kohler, Leonhard Buck, Patricia Schließer, Oscar Weische, Julian Risch, Jakob Christoph Voran, Jonas Jarczyk, Philipp Nuhn, Severin Rodler

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kohler, J., Buck, L., Schließer, P., et al. (2026). Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.05.010

Related articles

• Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery · Nature Reviews Urology · 2026 · Cites or is cited by this article
• Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Universally offered germline testing in upper tract urothelial carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Automated algorithm for surgical outcomes abstraction for cystectomy · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Featured SUO Fellow: Parth Thakker, MD · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal